A China Phase IV trial of VAL-083 to treat patients with refractory and relapsed non-small cell lung cancer (NSCLC) is slated by U.S.-based DelMar Pharmaceuticals and China's Guangxi Wuzhou Pharmaceuticals after approval by the China FDA. The trial will test whether the candidate is effective against TKI-resistant NSCLC. "The study will enroll up to 20 adult patients with NSCLC in an open-label post market Phase IV clinical trial to investigate the activity of VAL-083 in NSCLC patients who have failed standard platinum doublet therapy," DelMar said in a release, adding that Guangxi Wuzhou will fund the VAL-083 clinical research in China and DelMar is responsible for management of the clinical trials. Release